Hemostemix Inc.

PNK:HMTXF

$0.056 USD

-$0.02 (-28.21%)

Volume
10.07K
Average Volume
15.17K
Market Capitalization
$6.94M
P/E Ratio
-3.38
Dividend Yield
0.00%
Price Target
$
Year High
$0.08
Year Low
$0.02
Payout Ratio
$0.00
Current Ratio
$0.07

Industry, Sector & symbol

Stock Exchange Other OTC
CEO Mr. Thomas A. Smeenk B.A., BA Hons
Industry Biotechnology
Sector Healthcare
Current Symbol HMTXF
CUSIP None
CIK None
Web https://www.hemostemix.com
Phone None
Currency USD
Employees None
Country CA

Liquidity

Debt-to-Equity Ratio -0.55
Payout Ratio 0.00
Current Ratio 0.07
Quick Ratio 0.07
Cash Ratio 0.03

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow 0.00
Price / Cash Flow -29.41
Price / Book -0.78

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.0303
Trailing P/E Ratio -3.38
PEG Ratio 0.27
P/E Growth 0.27
Net Income $-2.5M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity 25.45%
Return on Assets -794.05%

Financials Score

AltmanZ Score -402.17
Piotroski Score 1.00
Working Capital -3.25M
Total Assets 243.78K
Ebit -1.3M
Market Cap 6.94M
Total Liabilities 8.6M

Poll Results

About Hemostemix Inc. (PNK:HMTXF) Stock

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada. ...

Hemostemix Announces $2,675,981 Private Placement Including Second Tranche of $833,258

2024-11-28 17:42:00

Calgary, Alberta--(Newsfile Corp. - November 28, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its second and final tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $833,258 (the "Offering"). The Offering consisted of the issuance of an aggregate of 16,665,160 Units at a price of $0.05 per Unit.

Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway

2024-11-25 13:43:00

Calgary, Alberta--(Newsfile Corp. - November 25, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, focusing on revenue, it has retained social media experts to educate and sell caregivers and individuals suffering from Chronic Limb Threatening Ischemia ("CLTI"), Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy, and Congestive Heart Failure, an ACP-01 treatment, available under special access programs. ACP-01 is a break-through treatment for no-option cardiovascular disease patients.

Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement

2024-10-31 16:04:00

Calgary, Alberta--(Newsfile Corp. - October 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its first tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $1,842,723 (the "Offering"). The Offering consisted of the issuance of an aggregate of 36,854,475 Units at a price of $0.05 per Unit.

Hemostemix's Private Placement

2024-10-11 08:29:00

Calgary, Alberta--(Newsfile Corp. - October 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $4,000,000 of financing in tranches from the sale of Common Shares and Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each Warrant entitling the holder to acquire one Common Share at a price of $0.12 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.

Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01

2024-08-01 22:03:00

Calgary, Alberta--(Newsfile Corp. - August 1, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it and CytoImmune Therapuetics ("CytoImmune") today signed a binding and funded definitive Manufacturing Services Agreement that re-establishes production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico. CytoImmune Therapeutics, Toa Baja, Puerto Rico To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/5065/218540_1be360ece42ada77_003full.jpg Hemostemix and CytoImmune have successfully completed the initial setup of the manufacturing facility and are on track to produce the first ACP-01 therapy by Q1 2025.

Frequently Asked Questions

What is the current Hemostemix Inc. (HMTXF) stock price?

Hemostemix Inc.(PNK:HMTXF) stock price is $0.056 in the last trading session. During the trading session, HMTXF stock reached the peak price of $0.079 while $0.024 was the lowest point it dropped to. The percentage change in HMTXF stock occurred in the recent session was --28.21% while the dollar amount for the price change in HMTXF stock was -$-0.02.

HMTXF's industry and sector of operation?

The PNK listed HMTXF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of HMTXF?

Mr. Thomas A. Smeenk B.A., BA Hons | Co-Founder, President, Chief Executive Officer & Director
Dr. Fraser C. Henderson Sr., M.D. | Chief Medical Officer
Ms. Christina Wu CPA | Interim Chief Financial Officer
Mr. Peter Pavlin | Vice President of Operations
|

How many employees does HMTXF have?

Number of HMTXF employees currently stands at None. HMTXF operates from 707-7th Avenue SW, Calgary, AB T2P 3H6, CA.

Link for HMTXF official website?

Official Website of HMTXF is: https://www.hemostemix.com

How do I contact HMTXF?

HMTXF could be contacted at phone #None and can also be accessed through its website. HMTXF operates from 707-7th Avenue SW, Calgary, AB T2P 3H6, CA.

How many shares of HMTXF are traded daily?

The average number of HMTXF shares traded daily for last 3 months was 15.17K.

What is the market cap of HMTXF currently?

The market value of HMTXF currently stands at $6.94M with its latest stock price at $0.056